These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7997892)

  • 1. Extraction methods of glycosaminoglycans from biologic fluids.
    Bianchini P; Mascellani G; Osima B; Parma B; Bergonzini G; Giusti P
    Semin Thromb Hemost; 1994; 20(2):205-13. PubMed ID: 7997892
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of low molecular weight heparins.
    Harenberg J
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():12-8. PubMed ID: 1962899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.
    Harenberg J; Casu B; Guerrini M; Malsch R; Naggi A; Piazolo L; Torri G
    Semin Thromb Hemost; 2002 Aug; 28(4):343-54. PubMed ID: 12244481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disaccharide analysis and molecular mass determination to microgram level of single sulfated glycosaminoglycan species in mixtures following agarose-gel electrophoresis.
    Volpi N
    Anal Biochem; 1999 Sep; 273(2):229-39. PubMed ID: 10469494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV; Kalishevskaia TM; Bako N
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligo-heparin action on endogenous glycosaminoglycans. Pharmacokinetics: direct and mediated effects.
    Bergonzini G; Parma B; Liverani L; Prete A; Mascellani G; Bianchini P
    Semin Thromb Hemost; 1994; 20(3):274-80. PubMed ID: 7824962
    [No Abstract]   [Full Text] [Related]  

  • 10. Competitive inhibition of myosin ATPase activity by different molecular weight heparins.
    Volpi N; Bianchini P; Bolognani L
    Biochem Int; 1991 May; 24(2):243-53. PubMed ID: 1656981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
    Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
    Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-factor Xa determination in blood: a new method for controlling heparin therapy.
    Harenberg J; Haaf B; Schäfer M; Dempfle CE; Stehle G; Heene DL
    Semin Thromb Hemost; 1993; 19 Suppl 1():79-85. PubMed ID: 8395736
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin.
    Dawes J
    Acta Chir Scand Suppl; 1990; 556():68-74. PubMed ID: 1963020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
    Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
    J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of low molecular weight glycosaminoglycans from marine mollusc Amussium pleuronectus (linne) using chromatography.
    Saravanan R; Shanmugam A
    Appl Biochem Biotechnol; 2010 Mar; 160(3):791-9. PubMed ID: 19184547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The behavior of unfractionated and low-molecular heparin in the body of the rat].
    Khlgatian SV; Umarova BA; Sahpiro FB; Strukova SM
    Dokl Akad Nauk SSSR; 1990; 313(2):509-11. PubMed ID: 1963137
    [No Abstract]   [Full Text] [Related]  

  • 20. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.